DirkJan Hijnen
Erasmus Universiteit Rotterdam
H-index: 38
Europe-Netherlands
Top articles of DirkJan Hijnen
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Navigating the Evolving Landscape of Atopic Dermatitis: Challenges and Future Opportunities: the 4 th Davos Declaration | C Traidl-Hoffmann J Afghani C Akdis M Akdis A Handan | 2024/3/26 | |
Upadacitinib treatment in a real‐world difficult‐to‐treat atopic dermatitis patient cohort | Journal of the European Academy of Dermatology and Venereology | Anne R Schlösser Neill Boeijink Jill Olydam Tamar EC Nijsten DirkJan Hijnen | 2024/2 |
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two … | American journal of clinical dermatology | Jonathan I Silverberg Melinda J Gooderham Amy S Paller Mette Deleuran Christopher G Bunick | 2024/3/25 |
mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses | Journal of Autoimmunity | Jet van den Dijssel Mariël C Duurland Veronique AL Konijn Laura YL Kummer Ruth R Hagen | 2024/4/1 |
Treat‐to‐target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitis | Yael Renert‐Yuval Ester Del Duca Bernd Arents Robert Bissonnette Aaron M Drucker | 2024/1 | |
Suppressed IgG4 class switching in dupilumab‐and TNF inhibitor‐treated patients after mRNA vaccination | Allergy | Anika M Valk Jim BD Keijser Koos PJ van Dam Eileen W Stalman Luuk Wieske | 2024/3/4 |
Tralokinumab for moderate-to-severe atopic dermatitis patients: first daily practice results. | Clinical and Experimental Dermatology | AR Schlösser M Shareef J Olydam TEC Nijsten DJ Hijnen | 2023/1/26 |
Reducing scratching behavior in atopic dermatitis patients using the EMDR treatment protocol for urge: A pilot study | Frontiers in Medicine | Mathijs R de Veer Rick Waalboer-Spuij Dirk Jan Hijnen Do Doeksen Jan J Busschbach | 2023/4/4 |
Real‐world effectiveness of abrocitinib treatment in patients with difficult‐to‐treat atopic dermatitis | Journal of the European Academy of Dermatology and Venereology | JI Olydam AR Schlösser P Custurone TEC Nijsten D Hijnen | 2023/12 |
Suppressed IgG4 class switching in dupilumab-and TNF inhibitor-treated patients after repeated SARS-CoV-2 mRNA vaccination | medRxiv | Anika M Valk Jim BD Keijser Koos van Dam Eileen Stalman Luuk Wieske | 2023 |
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity | BMC Infectious Diseases | Koos PJ Van Dam Adriaan G Volkers Luuk Wieske Eileen W Stalman Laura YL Kummer | 2023/5/17 |
42262 Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 … | Journal of the American Academy of Dermatology | Jonathan I Silverberg Mette Deleuran Linda S Gold Christopher G Bunick Dirk Jan Hijnen | 2023/9/1 |
Needs and preferences of patients regarding atopic dermatitis care in the era of new therapeutic options: a qualitative study | Archives of Dermatological Research | Linde EM de Wijs Sven van Egmond Arjan CA Devillers Tamar Nijsten DirkJan Hijnen | 2023/1 |
Digital Outcome Measurement to Improve Care for Patients With Immune-Mediated Inflammatory Diseases: Protocol for the IMID Registry | JMIR Research Protocols | Agnes EM Looijen Reinier CA van Linschoten Jan-Dietert Brugma Dirk Jan Hijnen Pascal HP de Jong | 2023/3/30 |
Prediction of response to dupilumab treatment | British Journal of Dermatology | DirkJan Hijnen Jill Olydam | 2023/6 |
Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice | Anne R Schlösser Madena Shareef Jill Olydam Tamar EC Nijsten Dirk Jan Hijnen | 2023/5 | |
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations | Journal of autoimmunity | Koos PJ van Dam Luuk Wieske Eileen W Stalman Laura YL Kummer Jesse Roosen | 2023/2/1 |
Impact of the first SARS-CoV-2 lockdown on adherence to biological treatment in patients with immune-mediated inflammatory diseases in the Netherlands | Patient preference and adherence | Romy van der Groef Pascal HP de Jong Dirk Jan Hijnen Christien J van der Woude Jan AM van Laar | 2023/12/31 |
Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases | Annals of the rheumatic diseases | Luuk Wieske Eileen W Stalman PJ Koos van Dam Laura Y Kummer Maurice Steenhuis | 2023/6/1 |
EASI p-EASI: predicting disease severity in patients with atopic dermatitis treated with Tralokinumab | The Journal of investigative dermatology | Jill I Olydam Linde EM de Wijs Willem A Dik Mads A Røpke Joel Correa Da Rosa | 2022/12 |
Co-Authors
